Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases.

Young LR, Vandyke R, Gulleman PM, Inoue Y, Brown KK, Schmidt LS, Linehan WM, Hajjar F, Kinder BW, Trapnell BC, Bissler JJ, Franz DN, McCormack FX.

Chest. 2010 Sep;138(3):674-81. doi: 10.1378/chest.10-0573. Epub 2010 Apr 9.

2.

Role of serum vascular endothelial growth factor D in discrimination of patients with polycystic lung diseases.

Radzikowska E, Jaguś P, Skoczylas A, Sobiecka M, Chorostowska-Wynimko J, Wiatr E, Kuś J, Roszkowski-Śliż K.

Pol Arch Med Wewn. 2013;123(10):533-8. Epub 2013 Sep 24.

3.

Correlation of serum vascular endothelial growth factor-D concentration with clinical presentation and course of lymphangioleiomyomatosis.

Radzikowska E, Jaguś P, Sobiecka M, Chorostowska-Wynimko J, Wiatr E, Kuś J, Roszkowski-Śliż K.

Respir Med. 2015 Nov;109(11):1469-75. doi: 10.1016/j.rmed.2015.09.005. Epub 2015 Sep 12.

4.

The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM).

Xu KF, Zhang P, Tian X, Ma A, Li X, Zhou J, Zeng N, Gui YS, Guo Z, Feng R, Zhang W, Sun W, Cai B.

Respir Med. 2013 Feb;107(2):263-8. doi: 10.1016/j.rmed.2012.10.006. Epub 2012 Nov 3.

5.

Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement.

Glasgow CG, Avila NA, Lin JP, Stylianou MP, Moss J.

Chest. 2009 May;135(5):1293-1300. doi: 10.1378/chest.08-1160.

6.

Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis.

Seyama K, Kumasaka T, Souma S, Sato T, Kurihara M, Mitani K, Tominaga S, Fukuchi Y.

Lymphat Res Biol. 2006;4(3):143-52.

PMID:
17034294
7.

Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis.

Chang WY, Cane JL, Blakey JD, Kumaran M, Pointon KS, Johnson SR.

Respir Res. 2012 Apr 18;13:34. doi: 10.1186/1465-9921-13-34.

8.

Lymphangioleiomyomatosis: differential diagnosis and optimal management.

Xu KF, Lo BH.

Ther Clin Risk Manag. 2014 Aug 21;10:691-700. doi: 10.2147/TCRM.S50784. eCollection 2014. Review.

9.

Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis.

Young LR, Inoue Y, McCormack FX.

N Engl J Med. 2008 Jan 10;358(2):199-200. doi: 10.1056/NEJMc0707517. No abstract available.

10.

[Lymphangioleiomyomatosis - new concepts on pathogenesis, diagnosis and treatment].

Sobiecka M.

Wiad Lek. 2016;69(2 Pt 1):123-9. Polish.

PMID:
27421126
11.

Efficacy and safety of transbronchial lung biopsy for the diagnosis of lymphangioleiomyomatosis: A report of 24 consecutive patients.

Koba T, Arai T, Kitaichi M, Kasai T, Hirose M, Tachibana K, Sugimoto C, Akira M, Hayashi S, Inoue Y.

Respirology. 2017 Sep 28. doi: 10.1111/resp.13190. [Epub ahead of print]

PMID:
28960664
12.

Effect of fasting on the size of lymphangioleiomyomas in patients with lymphangioleiomyomatosis.

Taveira-DaSilva AM, Jones AM, Julien-Williams P, Shawker T, Glasgow CG, Stylianou M, Moss J.

Chest. 2015 Oct;148(4):1027-1033. doi: 10.1378/chest.15-0456.

13.

Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis.

Atochina-Vasserman EN, Abramova E, James ML, Rue R, Liu AY, Ersumo NT, Guo CJ, Gow AJ, Krymskaya VP.

Am J Physiol Lung Cell Mol Physiol. 2015 Dec 15;309(12):L1447-54. doi: 10.1152/ajplung.00262.2015. Epub 2015 Oct 2.

14.

Involvement of lymphatics in lymphangioleiomyomatosis.

Glasgow CG, Taveira-DaSilva A, Pacheco-Rodriguez G, Steagall WK, Tsukada K, Cai X, El-Chemaly S, Moss J.

Lymphat Res Biol. 2009 Dec;7(4):221-8. doi: 10.1089/lrb.2009.0017.

15.

Evaluation of the extent of pulmonary cysts and their association with functional variables and serum markers in lymphangioleiomyomatosis (LAM).

Baldi BG, Araujo MS, Freitas CS, da Silva Teles GB, Kairalla RA, Dias OM, Pereira DA, Pimenta SP, Carvalho CR.

Lung. 2014 Dec;192(6):967-74. doi: 10.1007/s00408-014-9641-2. Epub 2014 Sep 9.

PMID:
25201087
16.

Similar trends in serum VEGF-D levels and kidney angiomyolipoma responses with longer duration sirolimus treatment in adults with tuberous sclerosis.

Malinowska IA, Lee N, Kumar V, Thiele EA, Franz DN, Ashwal S, Sagalowsky A, Dimario FJ Jr, Cutler D, Krueger D, Camposano S, Paolini J, Dabora SL.

PLoS One. 2013;8(2):e56199. doi: 10.1371/journal.pone.0056199. Epub 2013 Feb 20.

17.

Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial.

Young L, Lee HS, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Downey GP, Swigris JJ, Taveira-DaSilva AM, Krischer JP, Trapnell BC, McCormack FX; MILES Trial Group.

Lancet Respir Med. 2013 Aug;1(6):445-52.

18.

[Sporadic Lymphangioleiomyomatosis (sLAM) and Tuberous Sclerosis Complex (TSC) - Pulmonary Manifestations].

Brakemeier S, Grohé C, Bachmann F, Budde K.

Pneumologie. 2017 Feb;71(2):86-95. doi: 10.1055/s-0042-111522. Epub 2016 Sep 1. Review. German.

PMID:
27585353
19.

High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex.

Costello LC, Hartman TE, Ryu JH.

Mayo Clin Proc. 2000 Jun;75(6):591-4.

PMID:
10852420
20.

Lymphangioleiomyomatosis screening in women with tuberous sclerosis.

Cudzilo CJ, Szczesniak RD, Brody AS, Rattan MS, Krueger DA, Bissler JJ, Franz DN, McCormack FX, Young LR.

Chest. 2013 Aug;144(2):578-585. doi: 10.1378/chest.12-2813.

PMID:
23539171

Supplemental Content

Support Center